Increasing Access to Treatment for HIV and Hepatitis via Patient Assistance Programs and Cost-Sharing Assistance Programs

By Amanda Bowes, Associate, Health Care Access and Viral Hepatitis, NASTAD

Patient Assistance ProgramsThe treatment landscape for both HIV and hepatitis C (HCV) is evolving in exciting and dramatic ways. This excitement is often curbed, however, by high priced drugs and/or restrictive insurance practices that impacted populations face in accessing health care services.  Continue reading

Increasing Access to Treatment for HIV and Hepatitis via Patient and Cost-Sharing Assistance Programs

By Amanda Bowes, Associate, Health Care Access and Viral Hepatitis, NASTADPatient Assistance Programs

The treatment landscape for both HIV and hepatitis C (HCV) is evolving in exciting and dramatic ways. This excitement is often curbed, however, by high priced drugs and restrictive insurance practices that impacted populations face when accessing health care services. While the Affordable Care Act (ACA) includes an unprecedented expansion of access to both private and public health insurance, the cost of insurance (i.e., premiums, co-payments, co-insurance and deductibles) remain too high for some individuals, even with the availability of federal subsidies. Continue reading

How Meaningful Community Engagement Can Help End HIV

By Maria Courogen, Director, Office of Infectious Disease, Washington State Department of Health

Maria Courogen, Washington State Department of Health

Maria Courogen, Washington State Department of Health

As I began my tenure as NASTAD’s chair in May 2014, I was reminded of the great work that my immediate predecessors, Dawn Fukuda—Director of the Office of HIV/AIDS at the Massachusetts Department of Public Health—and Randy Mayer—Chief of the Bureau of HIV, STD and Hepatitis for the Iowa Department of Public Health—led during their time at the helm. It was a privilege to serve as an officer during both of their terms, as Randy created conversation regarding HIV criminalization and Dawn discussed the transformative power of the Affordable Care Act in the fight against HIV. The themes and work that resulted have pushed us further toward our shared mission of raising the bars as we strive to reach the goals laid out by the President’s National HIV/AIDS Strategy across all of our jurisdictions, for all populations. Continue reading

I Have My Protection—And It’s Not a Condom

By Blake Rowley, Manager, Health Equity & Prevention, NASTAD

Originally published by The Black AIDS Institute

Blake Rowley

Blake Rowley

Like most other Black men, I have had extremely inconsistent engagement with healthcare. If I’m not sick, why go? Until recently, the only time I really cared to access any type of care was when I was getting tested for HIV and other STIs.

In 2012, while conducting research at Fenway Health, I learned that multiple studies were trying to assess how effective taking one pill, once a day, would be at preventing HIV infection. My colleagues and I would joke about taking this pill once it became available, if it was successful. And then “BOOM,” there it was—a one-a-day pill that could prevent HIV by close to 100 percent. Continue reading

ADAP Crisis Task Force Announces Groundbreaking Agreement with AbbVie for Hepatitis C Treatment Viekira Pak™

ADAP Crisis Task Force Announces Groundbreaking Agreement with AbbVie for Hepatitis C Treatment Viekira Pak 

FOR IMMEDIATE RELEASE
Contact:  Britten Pund
202-434-8090
bpund@NASTAD.org

AbbVieJanuary 15, 2015, Washington, DC – The ADAP Crisis Task Force (Task Force) has reached a new pricing agreement between AbbVie and AIDS Drug Assistance Programs (ADAPs) for Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) for the treatment of hepatitis C (HCV). AbbVie is the first company to offer a discount on the ADAP price of an HCV medication in the era of new curative HCV treatments. The agreed-upon ADAP price for Viekira Pak, negotiated between the Task Force and AbbVie, reflects voluntary discounts and rebates that are significantly lower than the wholesale acquisition cost (WAC).  While many ADAPs may not be able to add Viekira Pak to their formularies due to fiscal constraints, this agreement recognizes the importance of access to hepatitis C medications for people living with HIV and demonstrates good faith that access at a discounted price may lead to formulary inclusion. ADAPs make individual decisions about adding new medications to their formularies. Continue reading